Granted Patent B2

US 12,473,269 · App. 18/511,612 · Granted Nov 18, 2025

Inventors: Christopher L. Rinsch (Lausanne, CH); Penelope Andreux (Eclepens, CH); Jonathan Mark Sutton (Harlow, GB); Eileen Mary Seward (Harlow, GB); Jamie D. Knight (Harlow, GB); Ian Linney (London, GB); Peter C. Sennhenn (Munich, DE); Said Oumouch (Wittenheim, FR); Florent Beaufils (Bartenheim, FR); Thomas Christian Fessard (Küsnacht, CH)

Assignee: Vandria SA

C07D311/80C07D217/24C07D279/02C07D407/12C07D491/04C07D491/107C07D493/04C07D493/10

Abstract

Claims (24)

1 . A compound of Formula (Ie):

wherein

A is

R 2 and R 7 are each OH;

R 1 and R 8 are each H; and

R 3 , R 4 , R 5 , and R 6 are independently selected from H, halogen, and alkyl;

or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 , wherein R 1 , R 3 , R 4 , R 5 , R 6 , and R 8 are each H.

3 . The compound of claim 1 , wherein one of R 3 , R 4 , R 5 , and R 6 is not H.

4 . The compound of claim 1 , wherein two of R 3 , R 4 , R 5 , and R 6 are not H.

5 . The compound of claim 1 , wherein the compound is selected from:

6 . The compound of claim 1 , wherein the compound is selected from:

 or

or a pharmaceutically acceptable salt thereof.

7 . The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

8 . The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9 . A pharmaceutical composition comprising a compound of claim 1 ; and a pharmaceutically acceptable carrier.

10 . The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

11 . A pharmaceutical composition comprising a compound of claim 10 ; and a pharmaceutically acceptable carrier.

12 . The compound of claim 1 , wherein the compound is selected from:

or a pharmaceutically acceptable salt thereof.

Assignments (7)

Continuity (3)

References Cited (157)